Table 2.

The clinical trials of oncolytic viruses in patients with melanoma.

Oncolytic Virus	Clinical Trial Phase	Administration Route	Combination	Status	Trial No.	References
T-VEC (Talimogene Laherparepvec)	I	IT	----	Completed	PMID17121894	[29]
	II	IT	----	Completed	NCT00289016	[30]
	Launched	IT	----	Completed	NCT01368276, NCT00769704	[27,31,32,33,34]
	II	IT	Ipilimumab	Completed	NCT01740297	[35]
	Ib		Pembrolizumab	Completed	NCT02263508	[36]
	II	IT	Pembrolizumab	Recruiting	NCT02965716
	I	IT	BRAF and MEK inhibitors	Recruiting	NCT03088176
	III	IT	Dacarbazine, temozolomide	Recruiting	NCT02288897
	II		Radiation	Recruiting	NCT02819843
HF10 (Canerpaturev—C-REV)	I	IT	----	Completed	NCT01017185	[39]
	II	IT	----	Ongoing	NCT03153085
	II	IT	Ipilimumab	Completed	NCT02272855	[40,41]
	II	IT	Nivolumab	Recruiting	NCT03259425
OrienX010	I	IT	----	Recruiting	NCT03048253
Oncos-102	I	IT	Cyclophosphamide pembrolizumab	Recruiting	NCT03003676
ICOVIR-5	I	IT	----	Completed Not reported	NCT01864759
Pexa Vec/JX-594	I	IV	----	Completed	PMID10505851	[54]
	II	IT	----	Completed	NCT00429312	[55]
Coxsackievirus A21 (CVA21) Cavatak	I	IT	----	Completed	NCT00438009	[44,45]
	II	IT	----	Completed	NCT01227551	[46]
	I	IT	Ipilimumab	Recruiting	NCT02307149	[47,48]
	I	IT	Pembrolizumab	Recruiting	NCT02565992
Pelareorep (Reolysin®)	I	IV	----	Completed	PMID: 18981012	[51]
	II	IV	----	Completed	NCT00651157	[52]
	II	IV	Carboplatin/paclitaxel	Completed	NCT00984464	[53]

Abbreviation: IT—intratumoral route; IV—intravenous.